Latest News & Features
Europe
With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its blockbuster blood thinner from generics. Marisa Woutersen finds Bayer’s outside litigation counsel ready for anything. 31 March 2025
Americas
Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes. 27 March 2025
Europe
Advocate general recommends upholding €60.48 million fine against Teva and Cephalon for anti-competitive modafinil settlement. 27 March 2025
Careers
Combining USPTO work with a background in molecular biology, immunology, and plant biochemistry, the new counsel brings patent practitioner and examiner skills to the firm. 27 March 2025
Americas
Court of Appeals rules defence costs in Hatch-Waxman cases are deductible as ordinary business expenses | US IRS stands to pay tax rebate to generics manufacturer. 25 March 2025
Americas
Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees helped ProfoundBio use confidential tech to improve its cancer treatment pipeline ahead of Genmab acquisition. 25 March 2025
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo. 25 March 2025
Europe
New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial molecular imaging products. 20 March 2025
Americas
Trio files multiple patent infringement lawsuits to protect blockbuster prostate cancer drug | Latest suits target Hetero and Aizant, following similar actions against Apotex, BDR Pharmaceuticals, and CIPLA. 20 March 2025
Americas
Companies are transforming IP from a defensive tool into a revenue-generating powerhouse. Marisa Woutersen at the WIPR Summit 2025 hears trends in licensing, platform-based monetisation, and litigation funding. 18 March 2025